SHAWNEE MISSION, Kan., April 23 /PRNewswire-FirstCall/ -- Bayer said it is
pleased at the results of two independent scientific studies that show banning
the use of Baytril(R) 3.23% enrofloxacin for the treatment of air sacculitis,
a pneumonia-like infection in poultry, could potentially compromise food
safety and have a significant negative impact on human health.
The studies, conducted at the University of Georgia by Dr. Scott Russell
and Dr. John Glisson, validate Bayer's position that the prudent use of
Baytril for the control of mortality associated with E. coli in chickens and
mortality associated with E. coli and P. multocida (fowl cholera) in turkeys
helps to ensure a safe food supply.
The study conducted by Dr. Glisson showed that when evaluating treatment
options, Baytril was the only antibiotic found to be effective in eliminating
air sacculitis from broiler chickens.
Dr. Russell's study showed that Campylobacter counts were significantly
higher on chicken carcasses derived from flocks that tested positive for air
sacculitis. In addition, chickens with air sacculitis typically have lower
body weights. Weight variations significantly contribute to errors during
processing that lead to increased levels of bacterial contamination on the
processed poultry meat.
"These studies strongly support the continued therapeutic use of Baytril
for poultry and clearly identify the human health benefit, a factor that has
not yet been fully considered by FDA," said John B. Payne, president and
general manager, Bayer HealthCare LLC, Animal Health Division.
About Bayer
Bayer, the maker of Baytril(R) (enrofloxacin) 3.23% Concentrate
Antimicrobial Solution, is a worldwide leader in parasite control and
prescription pharmaceuticals for dogs, cats, horses, cattle and poultry. In
addition, the company is increasing its presence in the hygiene market with
products to control pests in the environment. Bayer Animal Health is a
division of Bayer HealthCare LLC, and its U.S. operations are headquartered in
Shawnee, Kansas.
Bayer HealthCare, a subgroup of Bayer AG (NYSE: BAY) with annual sales
amounting to some 10 billion Euro, is one of the world's leading, innovative
companies in the health care and medical products industry. Bayer HealthCare
combines the global activities of the Animal Health, Biological Products,
Consumer Care, Diagnostics and Pharmaceutical divisions. More than
34,000 employees work for Bayer HealthCare worldwide. Our work at Bayer
HealthCare is to discover and manufacture innovative products for the purpose
of improving human and animal health worldwide. Our products enhance
well-being and quality of life by diagnosing, preventing and treating disease.
Forward-Looking Statements
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in our public reports filed with the Frankfurt
Stock Exchange and with the U.S. Securities and Exchange Commission (including
our Form 20-F). The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or
developments.
SOURCE Bayer
 back to top
Related links:
http://www.healthypoultry.com
http://www.bayerus.com
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/092575.html
CONTACT:
Bob Walker of Bayer, +1-412-777-5666,
bob.walker.b@bayer.com
|
